Anders Gustavsson
Overview
Explore the profile of Anders Gustavsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
1489
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hallberg S, Rolfson O, Karppinen J, Schiottz-Christensen B, Stubhaug A, Fischer M, et al.
Scand J Pain
. 2022 Jul;
23(1):126-138.
PMID: 35858277
Objectives: Osteoarthritis (OA) and chronic low back pain (CLBP) are common musculoskeletal disorders with substantial patient and societal burden. Nordic administrative registers offer a unique opportunity to study the impact...
12.
Gustavsson A, Norton N, Fast T, Frolich L, Georges J, Holzapfel D, et al.
Alzheimers Dement
. 2022 Jun;
19(2):658-670.
PMID: 35652476
Introduction: Global estimates on numbers of persons in early stages of Alzheimer's disease (AD), including prodromal and preclinical, are lacking, yet are needed to inform policy decisions on preventive measures...
13.
Visuri I, Eriksson C, Olen O, Cao Y, Mardberg E, Grip O, et al.
Aliment Pharmacol Ther
. 2021 Aug;
54(6):848-849.
PMID: 34425010
No abstract available.
14.
Visuri I, Eriksson C, Olen O, Cao Y, Mardberg E, Grip O, et al.
Aliment Pharmacol Ther
. 2021 Jul;
54(7):931-943.
PMID: 34286871
Background: Whether long-term effectiveness differs between anti-tumour necrosis factor (anti-TNF) agents is unknown. Aims: To examine drug survival of first-line anti-TNF agents and identify predictors of discontinuation. To reduce channelling...
15.
Van den Hurk W, Bergman I, Machado A, Bjermo J, Gustavsson A
J Int Neuropsychol Soc
. 2021 May;
28(2):188-202.
PMID: 34027854
Objective: Cognitive impairment is a key element in most mental disorders. Its objective assessment at initial patient contact in primary care can lead to better adjusted and timely care with...
16.
Gustavsson A, Raket L, Lilja M, Rutten-Jacobs L, Fues Wahl H, Bagijn M, et al.
Alzheimers Dement
. 2021 May;
17(11):1832-1842.
PMID: 33984179
Quality of life and health utility are important outcomes for patients with Alzheimer's disease (AD) and central for demonstrating the value of new treatments. Estimates in biomarker-confirmed AD populations are...
17.
Diaz A, Gove D, Nelson M, Smith M, Tochel C, Bintener C, et al.
Health Expect
. 2021 Apr;
24(3):757-765.
PMID: 33822448
Background: Dementia outcomes include memory loss, language impairment, reduced quality of life and personality changes. Research suggests that outcomes selected for dementia clinical trials might not be the most important...
18.
Landeiro F, Mughal S, Walsh K, Nye E, Morton J, Williams H, et al.
Alzheimers Res Ther
. 2020 Nov;
12(1):154.
PMID: 33208190
Background: Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer's disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is essential...
19.
Rombach I, Iftikhar M, Jhuti G, Gustavsson A, Lecomte P, Belger M, et al.
Qual Life Res
. 2020 Oct;
30(3):867-879.
PMID: 33068236
Purpose: The Quality of Life Alzheimer's Disease Scale (QoL-AD) is commonly used to assess disease specific health-related quality of life (HRQoL) as rated by patients and their carers. For cost-effectiveness...
20.
Gustavsson A, Pemberton-Ross P, Gomez Montero M, Hashim M, Thompson R
Expert Rev Pharmacoecon Outcomes Res
. 2020 Sep;
20(6):563-570.
PMID: 32951480
Introduction: Alzheimer's disease (AD) is a complex neurodegenerative disease, affecting millions of people worldwide and imposing heavy economic burdens to societies. Currently, only symptomatic treatments are available for patients, but...